Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.67 Consensus Price Target from Analysts

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have been assigned an average rating of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $28.6667.

Several equities research analysts recently commented on the company. HC Wainwright upped their target price on Kyverna Therapeutics from $10.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, October 27th. Wall Street Zen lowered Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Morgan Stanley set a $33.00 price target on Kyverna Therapeutics in a report on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Monday, December 29th. Finally, Wells Fargo & Company boosted their target price on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th.

Kyverna Therapeutics Trading Down 5.2%

Shares of KYTX opened at $7.68 on Friday. The firm’s fifty day simple moving average is $8.47 and its two-hundred day simple moving average is $6.80. Kyverna Therapeutics has a 12 month low of $1.78 and a 12 month high of $13.67. The stock has a market capitalization of $336.38 million, a P/E ratio of -2.06 and a beta of 3.45.

Insider Activity

In other news, major shareholder Biopartners Opportuni Westlake bought 133,333 shares of Kyverna Therapeutics stock in a transaction dated Thursday, December 18th. The stock was bought at an average cost of $7.50 per share, for a total transaction of $999,997.50. Following the purchase, the insider directly owned 869,317 shares in the company, valued at approximately $6,519,877.50. This represents a 18.12% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO Karen Marie Walker sold 23,998 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $12.20, for a total value of $292,775.60. Following the completion of the sale, the chief technology officer directly owned 22,636 shares of the company’s stock, valued at $276,159.20. The trade was a 51.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing.

Institutional Investors Weigh In On Kyverna Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. bought a new position in Kyverna Therapeutics in the 4th quarter valued at about $15,667,000. AIGH Capital Management LLC purchased a new stake in shares of Kyverna Therapeutics in the fourth quarter worth approximately $14,100,000. Balyasny Asset Management L.P. bought a new position in shares of Kyverna Therapeutics in the fourth quarter valued at approximately $9,220,000. Propel Bio Management LLC bought a new position in shares of Kyverna Therapeutics in the fourth quarter valued at approximately $6,267,000. Finally, Alyeska Investment Group L.P. purchased a new position in shares of Kyverna Therapeutics during the fourth quarter valued at approximately $5,640,000. 18.08% of the stock is owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.